PNAS:深度学习助力罕见戈谢病机制研究

2019-03-01 海北 MedSci原创

溶酶体酶葡糖脑苷脂酶-1(GCase)催化主要糖脂葡糖神经酰胺的裂解,成为葡萄糖和神经酰胺。缺乏完整功能的GCase导致其脂质底物在溶酶体中积累,引起戈谢病。

溶酶体酶葡糖脑苷脂酶-1(GCase)催化主要糖脂葡糖神经酰胺的裂解,成为葡萄糖和神经酰胺。缺乏完整功能的GCase导致其脂质底物在溶酶体中积累,引起戈谢病,这是一种常染色体隐性遗传疾病,表现出深刻的基因型-表型不一致。

已发现GBA1(编码GCase的基因)中超过250种引起疾病的突变,其中有一种突变,N370S,可以引起70%的疾病。

最近,研究人员使用了基于知识的对接方案,该方案考虑了蛋白质-蛋白质结合的实验数据,以在GCase和其已知的促进蛋白鞘脂激活蛋白C(SAPC)之间产生复合物。多尺度分子动力学模拟用于研究脂质自组装,膜插入和复合物的不同组分之间相互作用的动力学。深度学习被用于提出一个解释GCase激活机制的模型,这需要SAPC。

值得注意的是,研究人员发现,通过与SAPC的直接相互作用,稳定了底物结合位点入口处环的构象变化,并且由N370S和另一种常见突变L444P诱导的这种相互作用的丧失可以导致复合物的不稳定以及GCase活化的减少。

该研究结果为GCase的活化,以及N370S和L444P引起戈谢病的确切机制提供了原子级解释。


原始出处:

Romero R et al. Mechanism of glucocerebrosidase activation and dysfunction in Gaucher disease unraveled by molecular dynamics and deep learning. PNAS, 2019; doi: 10.1073/pnas.1818411116.


本文系梅斯医学(MedSci)原创编译整理,转载需授权

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2056198, encodeId=6bf7205619854, content=<a href='/topic/show?id=616b611e9bc' target=_blank style='color:#2F92EE;'>#机制研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61179, encryptionId=616b611e9bc, topicName=机制研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Sat Nov 09 04:30:00 CST 2019, time=2019-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1856279, encodeId=623f18562e98b, content=<a href='/topic/show?id=f32014428fc' target=_blank style='color:#2F92EE;'>#PNAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14428, encryptionId=f32014428fc, topicName=PNAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Fri Sep 06 06:30:00 CST 2019, time=2019-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1467431, encodeId=c5f0146e4314c, content=<a href='/topic/show?id=ef32e9539e8' target=_blank style='color:#2F92EE;'>#罕见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79539, encryptionId=ef32e9539e8, topicName=罕见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29f36868190, createdName=syscxl, createdTime=Sun Mar 03 04:30:00 CST 2019, time=2019-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=361785, encodeId=223a361e8558, content=收获很大, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJdPsia4L20fPsHW6YShBlhyTzQplazj2qoJo6bycbukbibF9ZwgPr3tnldI70SkfXRGCicYbZjgPy7g/132, createdBy=7ed32384080, createdName=小子一阿一, createdTime=Fri Mar 01 14:45:23 CST 2019, time=2019-03-01, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2056198, encodeId=6bf7205619854, content=<a href='/topic/show?id=616b611e9bc' target=_blank style='color:#2F92EE;'>#机制研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61179, encryptionId=616b611e9bc, topicName=机制研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Sat Nov 09 04:30:00 CST 2019, time=2019-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1856279, encodeId=623f18562e98b, content=<a href='/topic/show?id=f32014428fc' target=_blank style='color:#2F92EE;'>#PNAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14428, encryptionId=f32014428fc, topicName=PNAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Fri Sep 06 06:30:00 CST 2019, time=2019-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1467431, encodeId=c5f0146e4314c, content=<a href='/topic/show?id=ef32e9539e8' target=_blank style='color:#2F92EE;'>#罕见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79539, encryptionId=ef32e9539e8, topicName=罕见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29f36868190, createdName=syscxl, createdTime=Sun Mar 03 04:30:00 CST 2019, time=2019-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=361785, encodeId=223a361e8558, content=收获很大, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJdPsia4L20fPsHW6YShBlhyTzQplazj2qoJo6bycbukbibF9ZwgPr3tnldI70SkfXRGCicYbZjgPy7g/132, createdBy=7ed32384080, createdName=小子一阿一, createdTime=Fri Mar 01 14:45:23 CST 2019, time=2019-03-01, status=1, ipAttribution=)]
    2019-09-06 drwjr
  3. [GetPortalCommentsPageByObjectIdResponse(id=2056198, encodeId=6bf7205619854, content=<a href='/topic/show?id=616b611e9bc' target=_blank style='color:#2F92EE;'>#机制研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61179, encryptionId=616b611e9bc, topicName=机制研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Sat Nov 09 04:30:00 CST 2019, time=2019-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1856279, encodeId=623f18562e98b, content=<a href='/topic/show?id=f32014428fc' target=_blank style='color:#2F92EE;'>#PNAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14428, encryptionId=f32014428fc, topicName=PNAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Fri Sep 06 06:30:00 CST 2019, time=2019-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1467431, encodeId=c5f0146e4314c, content=<a href='/topic/show?id=ef32e9539e8' target=_blank style='color:#2F92EE;'>#罕见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79539, encryptionId=ef32e9539e8, topicName=罕见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29f36868190, createdName=syscxl, createdTime=Sun Mar 03 04:30:00 CST 2019, time=2019-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=361785, encodeId=223a361e8558, content=收获很大, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJdPsia4L20fPsHW6YShBlhyTzQplazj2qoJo6bycbukbibF9ZwgPr3tnldI70SkfXRGCicYbZjgPy7g/132, createdBy=7ed32384080, createdName=小子一阿一, createdTime=Fri Mar 01 14:45:23 CST 2019, time=2019-03-01, status=1, ipAttribution=)]
    2019-03-03 syscxl
  4. [GetPortalCommentsPageByObjectIdResponse(id=2056198, encodeId=6bf7205619854, content=<a href='/topic/show?id=616b611e9bc' target=_blank style='color:#2F92EE;'>#机制研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61179, encryptionId=616b611e9bc, topicName=机制研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Sat Nov 09 04:30:00 CST 2019, time=2019-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1856279, encodeId=623f18562e98b, content=<a href='/topic/show?id=f32014428fc' target=_blank style='color:#2F92EE;'>#PNAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14428, encryptionId=f32014428fc, topicName=PNAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Fri Sep 06 06:30:00 CST 2019, time=2019-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1467431, encodeId=c5f0146e4314c, content=<a href='/topic/show?id=ef32e9539e8' target=_blank style='color:#2F92EE;'>#罕见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79539, encryptionId=ef32e9539e8, topicName=罕见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29f36868190, createdName=syscxl, createdTime=Sun Mar 03 04:30:00 CST 2019, time=2019-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=361785, encodeId=223a361e8558, content=收获很大, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJdPsia4L20fPsHW6YShBlhyTzQplazj2qoJo6bycbukbibF9ZwgPr3tnldI70SkfXRGCicYbZjgPy7g/132, createdBy=7ed32384080, createdName=小子一阿一, createdTime=Fri Mar 01 14:45:23 CST 2019, time=2019-03-01, status=1, ipAttribution=)]
    2019-03-01 小子一阿一

    收获很大

    0

相关资讯

国际罕见病日 我国首部《戈谢病患者长期生存状况调查》出炉

在第11个国际罕见病日即将到来之际,中国首个罕见病慈善援助项目:中华慈善总会与赛诺菲中国合作开展的中华慈善总会思而赞慈善援助项目迎来了10周年庆典。会上我国首部《戈谢病患者长期生存状况调查(2019)》(以下简称:《生存调查》)正式发布。《生存调查》首次聚焦于我国戈谢病领域患者生活状况,依据思而赞慈善援助项目10年以来积累的戈谢病诊疗的真实世界数据,客观地反映了130余位戈谢病患者目前的生活状况。

首批罕见病药品增值税优惠正式落地 21个罕见病药品和4个原料药减征增值税

2月22日,财政部、海关总署、税务总局和国家药品监管局4部门联合下发《关于罕见病药品增值税政策的通知》(以下简称“通知”),首批罕见病药品增值税优惠正式落地。

数图说:罕见病用药格局概况

罕见病用药格局概况。

2.28:国际罕见病日:因你珍稀,所以珍惜

让我们多了解一点罕见病,理解并帮助他们,给予他们生的勇气。

罕见病日|有种罕见病“青睐”青壮年,13%有自杀倾向

当一种罕见病以中青年为“主要目标”,患病后可感觉障碍、肢体运动障碍、疲劳和平衡障碍,其生存现状会是如何?2018年5月,中华医学会神经病学分会牵头对全国49家医院、56位权威专家和1362名患者进行调研,患者分布全国31个省、自治区和直辖市(港澳台除外)。根据患者基本特征、疾病特征、诊疗情况、心理负担及经济负担五大方面,多维度揭示中国多发性硬化患者生存现状。在2月28日国际罕见病日到来之际,中

中美针对“罕见病”药物提出不同举措

罕见病虽小,却是一门大生意。《我不是药神》药物原型格列卫,最初就是以“孤儿药”获批,最后成为年销售峰值逼近50亿美元的超级“重磅炸弹”。在世界罕见病日(2月28日)即将到来之际,中美两国政府针对“罕见病”药物提出不同举措